Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31390568 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL2944859 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL18042534 | 0.98 | PPM1D (0.33) | PPM1D | |
| SCHEMBL18042506 | 0.98 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1795645 | 0.98 | PPM1D (0.33) | PPM1D | |
| SCHEMBL4333519 | 0.96 | PPM1D (0.33) | PPM1D | |
| SCHEMBL29768181 | 0.88 | PPM1D (0.32) | PPM1D | |
| SCHEMBL1015667 | 0.83 | PPM1D (0.34) | PPM1D | |
| SCHEMBL5831542 | 0.83 | PPM1D (0.34) | PPM1D | |
| SCHEMBL661089 | 0.83 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758545-B2 | Sensor with a scaffold having changeable conformations | UNIVERSITÉ DE FRIBOURG (CH) | 2017-09-12 | — | — | US | disclosed |
| US-20130266644-A1 | SENSOR | UNIVERSITE DE FRIBOURG (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012162210-A1 | RING CONSTRAINED CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20060252839-A1 | Pharmaceutical compositions | BIOGEM S.C.A.R.L. (IT) | 2006-11-09 | — | — | US | disclosed |
| US-20050124696-A1 | Pharmaceutical compositions | ROBERTS STANLEY M (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1487789-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Ltd. (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1456163-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| EP-1094060-B1 | New process for the preparation of retiferol derivatives | BASILEA PHARMACEUTICA AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003082813-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003051807-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| US-6437142-B1 | 10,10,10-TRIFLUORO-5,5-DIMETHYL-9-TRIETHYLSILANYLOXY-9-TRIFLUO ROMETHYL-DEC-7-ENAL REACTED WITH TRIETHYL PHOSPHONOACETATE OR ETHYL (TRIMETHYLSILYL) ACETATE AND THEN COUPLING WITH 2-MERCAPTO-BENZOTHIAZOLE | BASILEA PHARMACEUTICA AG (CH) | 2002-08-20 | — | — | US | disclosed |
| US-6403346-B1 | FOR TREATMENT/PREVENTION OF HYPERPROLIFERATIVE SKIN DISEASES (PSORIASIS) AND REVERSING CONDITIONS ASSOCIATED WITH PHOTODAMAGE | BASILEA PHARMACEUTICA AG (CH) | 2002-06-11 | — | — | US | disclosed |
| US-20020028975-A1 | Process for preparing retiferol derivatives | HILPERT HANS (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6310262-B1 | COUPLING CYCLOHEXANONE DERIVATIVE WITH BENZOTHIAZOLE DERIVATIVE TO FORM RETIFEROL DERIVATIVE | BASILEA PHARMACEUTICA AG (CH) | 2001-10-30 | — | — | US | disclosed |
| EP-1094060-A2 | New process for the preparation of retiferol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266644-A1 | SENSOR | NCS1, BID, CGAS | PPM1D 3115/4885 |
| US-20050124696-A1 | Pharmaceutical compositions | ADRM1, ARL1, UGT1A3 | PPM1D 4522/4885 |
| US-20060252839-A1 | Pharmaceutical compositions | ADK, SYMPK, CYP2J2 | PPM1D 4147/4885 |
| US-20020028975-A1 | Process for preparing retiferol derivatives | RBP1, RBP4, NR1H2 | PPM1D 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.